Joanna Brougher | Owner & Principal, BioPharma Law Group, PLLC, Biotech, Pharma and Medical Device IP and Corporate Co
BioPharma Law Group PLLC

Joanna Brougher, Owner & Principal, BioPharma Law Group, PLLC, Biotech, Pharma and Medical Device IP and Corporate Co, BioPharma Law Group PLLC

Joanna is a patent attorney who focuses her practice on all aspects of services related to patents in the life sciences. Joanna has experience counseling clients on the Hatch-Waxman Act and is monitoring developments involving biosimilars under the Biologics Price Competition and Innovation Act. Joanna is also an Adjunct Lecturer at the Harvard T.H. Chan School of Public Health and the Editor-in-Chief of the Journal of Commercial Biotechnology.  She regularly speaks or lectures on intellectual property-related topics and is a frequent author of articles related to patent law and healthcare.  In 2013, Joanna published a book called Intellectual Property and Health Technologies: Balancing Innovation and the Public's Health which examines the relationship between patents and public health in the context of medical technologies. Joanna received her J.D. degree from Boston College Law School, and is admitted to the Massachusetts and New York State Bars as well as the USPTO.

Appearances:



Biosimilars Day 1 - Tuesday 31st October 2017 @ 11:35

Plenary Roundtable Discussion Session

8 senior level tables hosted by thought leaders on key challenges and opportunities in antibody drug development. Participants are invited to join the group discussions on a topic of importance to them.

ROUNDTABLE 6 State of the BPCIA after the Supreme Court’s Ruling in Amgen v. Sandoz

Biosimilars Day 2 - Wednesday 1st November 2017 @ 14:35

Obtaining patent protection while operating in an "anti-patent" climate

Biosimilars Day 2 - Wednesday 1st November 2017 @ 15:25

Panel: Legal and IP strategies to strengthen biosimilar medicine developers

  • How Brexit will impact the IP landscape and business strategies for the sector
  • A competitiveness boost: what are the opportunities for biosimilar medicine developers?
  • Establishing sustainability for second medical use patents
  • How to take advantage of the IP and regulatory environments to grow the generic and value added medicines business
  • Antitrust case law and latest developments
  • Inconsistencies in the SPC case law

back to speakers